Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine TreatmentEdward M. Connor, James Balsley, Rhoda Sperling et al.|New England Journal of Medicine|1994Cited by 3.7k
Lymphocyte subsets in healthy children from birth through 18 years of ageWilliam T. Shearer, Stephen A. Spector, Howard M. Rosenblatt et al.|Journal of Allergy and Clinical Immunology|2003Cited by 828
Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: The Primary Immune Deficiency Treatment Consortium experienceWilliam T. Shearer, Morton J. Cowan|Journal of Allergy and Clinical Immunology|2013Cited by 343
Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective studyFederica Barzaghi, Rakesh K. Goyal, Alessandro Aiuti et al.|Journal of Allergy and Clinical Immunology|2017Cited by 313
Safety of the maternal–infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trial Group 076 StudyRhoda Sperling, Jean-François Delfraissy, David E. Shapiro et al.|AIDS|1998Cited by 166